Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,400.00
Bid: 12,400.00
Ask: 12,402.00
Change: 68.00 (0.55%)
Spread: 2.00 (0.016%)
Open: 12,350.00
High: 12,400.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Start Lower Ahead Of Trump Press Conference

Fri, 29th May 2020 08:51

(Alliance News) - Stock prices in London opened in the red on Friday, as worsening US–China relations overshadow optimism from the easing of coronavirus lockdowns across the globe.

The FTSE 100 index was down 36.50 points, or 0.6%, at 6,182.29 on Friday. Since the week began, the blue-chip index is up 2.8%, though it remains down 18% so far in 2020.

The mid-cap FTSE 250 index was down 58.89 points, or 0.3%, at 17,279.59, and the AIM All-Share index was down 0.2% at 873.60.

The Cboe UK 100 index was 0.8% lower at 10,446.43. The Cboe 250 was down 0.4% at 14,781.40, and the Cboe Small Companies down 0.1% at 12,120.78.

In mainland Europe, the CAC 40 in Paris was down 0.8%, while the DAX 30 in Frankfurt was down 1.1%.

"Risk-off is dominating as investors look ahead to Trump's response, provoked by China's crackdown on civil liberties in Hong Kong, Asia's financial hub," said City Index analyst Fiona Cincotta.

Trump said he will give a press conference Friday on China amid rising US-Chinese tensions over Hong Kong and the coronavirus fallout.

Trump told reporters of his plan for the press conference at an Oval Office meeting on Thursday, but gave no specific details of what he would be announcing.

Fears that China will use a new law to end Hong Kong's freedom as a semi-autonomous territory have prompted expectations that Trump plans to hit back, possibly signalling a wider economic confrontation between the two superpowers.

Washington and Beijing are already clashing over responsibility for the extent of the coronavirus pandemic, which originated in China but has caused devastation in the US. The US recorded 1,297 coronavirus deaths on Thursday, bringing its total to 101,573 since the global pandemic began, according to a tally kept by Johns Hopkins University.

The country has officially logged 1.7 million cases of the virus, far more than any other nation, the tracker kept by the Baltimore-based university showed. Trump blames that on China, although his domestic critics accuse him of mismanagement.

"The fear is that the US–China spat could hamper a fragile economic recovery from the coronavirus crisis," added Cincotta.

The Hang Seng index in Hong Kong closed down 0.7% on Friday. Elsewhere in China, the Shanghai Composite finished up 0.2%. In Japan, Tokyo's Nikkei 225 index closed down 0.2%.

On the London Stock Exchange, AstraZeneca was among the best performers in the blue-chip index, up 1.3%, after its phase 3 Adaura trial of Tagrisso in early-stage cell lung cancer found that the drug reduced the risk of disease recurrence or death by around 80%.

The detailed results were from a trial of Tagrisso, the brand name for osimertinib, after surgery in patients with "epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer after complete tumour resection with curative intent". EGFR mutations are associated with some lung cancers.

In the primary endpoint of disease-free survival in patients with stage 2 and 3A disease, treatment with Tagrisso reduced risk of disease recurrence or death by 83%. Disease-free survival in the overall trial population, covering stages 1B to 3A, found a 79% drop in the risk of disease recurrence or death.

At the two year mark, 89% of patients in the trial who had been treated with Tagrisso were still alive and disease free compared to a 53% figure in patients who were given a placebo.

Admiral Group was among the worst performers on Friday morning, down 1.6%, after Barclays cut the insurer to Equal Weight from Overweight.

Fresnillo was trading 1.5% lower after saying that it is responding to operational challenges caused by Covid-19 after a tough 2019. The Mexican gold miner said it has focused on responding to the Covid-19 over the past three months, implementing a range of safety measures across the business.

"Up to this point, we have had no officially confirmed Covid-19 cases originating from inside our operations," said Chair Alberto Bailleres. However, he noted that three colleagues were officially diagnosed from exposure outside.

Fresnillo also confirmed that the board and senior management took voluntary and temporary pay cuts to help the company get through this "unprecedented" situation.

Fresnillo said its operations are critical to the economies in which it operate, with mining now confirmed as an essential activity in Mexico.

"Operationally, 2019 was a more challenging year, as expected," said Bailleres.

Both silver and gold production fell from 2018 levels, due to lower-than-anticipated grades in its key mines. This also hurt Fresnillo's financial performance.

In the face of these operational challenges, the company said its response has been to increase the pace and scale of investments in a series of projects and take corrective actions to bring production back to acceptable levels in the short-term, and to achieve steady growth in future years.

"We are investing in infrastructure, plant and machinery including a state-of-the-art tunnel boring machine which is now being ramped up at Fresnillo - one of the first of its kind. We have also begun to define a new programme to control costs and increase productivity," said Bailleres.

Among the mid-caps, Provident Financial was the best performer, up 4.4% in early trade, after getting an upgrade from Jefferies to Buy from Hold.

B&M European Value Retail was the second-best performer in the FTSE 250 index, up 3.6%. B&M reported a strong end to the fourth quarter - which ran to March 28 - driven by exceptionally strong March performance in Grocery, with the B&M UK fascia like-for-like revenue up 6.6%.

Going forward, B&M said it experienced strong revenue growth in the first 8 weeks to May 23, with B&M UK fascia like-for-like revenue up 23%, driven by exceptionally strong Do It Yourself and Gardening categories, and despite a significant fall in customer count.

If DIY and Gardening categories are excluded, the B&M UK fascia like-for-like revenue over that 8 week period was up 10%.

"We have encountered exceptionally strong demand in our UK business over recent weeks. Customers have been coming to our stores much less frequently through the lockdown but their average spend has been much higher than normal," said Chief Executive Simon Arora.

"Clearly, there is also considerable uncertainty in relation to both the progression of Covid-19 and the economic outlook, and it is therefore hard to predict future trading levels," added Arora.

SIG was up 3.6% in the morning trading on Friday. The building products supplier announced plans to bring in a substantial new investor as part of an equity fundraise to deliver a new growth strategy, after swinging to a loss in 2019.

SIG reported a 9.0% decline in revenue in 2019 to GBP2.08 billion. On a like-for-like basis, sales declined by 7.6%.

SIG said its performance was hurt by market share losses in UK and Germany due to poor execution of transformation initiatives which, it believes, disconnected the business from its customers, suppliers and its front-line colleagues.

As a result, the company swung to pretax loss of GBP112.7 million in 2019 compared to GBP10.3 million profit a year prior.

SIG cut its dividend to 1.25 pence, having paid a 3.75p per share payout in 2018.

"The 2019 results, albeit in line with January guidance, are disappointing. However, the board has taken decisive action to address this performance. A new chief executive has been appointed and, this morning, we announced the appointment of a new chief financial officer," said Chair Andrew Allner.

SIG named Ian Ashton as permanent CFO and Simon King as a non-executive director, both with effect from the start of July.

Ashton replaces Kath Kearney-Croft, who had taken on the role of interim CFO back in February. Ashton will join SIG from Low & Bonar, where he has served as CFO.

Going forward, SIG said it has explored its wider funding options and is intending to raise GBP150 million in new equity in the coming weeks to strengthen its capital structure and enable the management team to deliver its new growth strategy. The equity raise will be led by US private equity firm Clayton, Dubilier & Rice, which will contribute up to GBP85 million and take an about 25% stake in SIG as a result.

In commodities, gold was quoted at USD1,721.98 an ounce early Friday, soft from USD1,722.65 late Thursday. Brent oil was at USD35.08 a barrel, up from USD34.45.

"Safe haven gold is building on gains from the previous session as tensions between the US and China mount, although the US dollar is slipping lower, decoupling from falling stocks," said City Index's Cincotta.

Against the yen, the dollar was trading at JPY107.19 early Friday in London, down from JPY107.60 late Thursday.

The pound was quoted at USD1.2350 early Friday, firm from USD1.2323 at the London equities close Thursday. The euro was at USD1.1100 early Friday, up from USD1.1067 late Thursday.

German retail sales slumped in April, the latest data from Destatis showed on Friday, with a separate release showing import prices also sank.

Retail sales were down 5.3% on a monthly basis and 6.5% annually in April, far steeper than falls of 4.0% and 1.2% recorded, respectively, for March.

Separately, the statistical body showed import prices were down 7.4% in April year-on-year, the sharpest fall recorded since 2009. In March, prices had fallen 5.5%.

The economic events calendar on Friday has eurozone inflation figures at 1000 BST. In the London afternoon, there are US personal consumption expenditure index numbers at 1330 BST - the core reading is the US Federal Reserve's preferred gauge of inflation.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more
30 Oct 2023 09:40

LONDON BROKER RATINGS: Jefferies cuts NatWest to underperform from buy

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
25 Oct 2023 11:04

PRESS: Soriot commits to five more years as AstraZeneca CEO - Times

(Alliance News) - Pascal Soriot has committed to remaining as chief executive officer of AstraZeneca PLC for another five years, The Times reported on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.